We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

By LabMedica International staff writers
Posted on 20 Feb 2026

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging for biomarker discovery and diagnostic development. More...

Laboratories also require scalable extraction methods that accommodate variable input volumes and multiple biofluids while preserving reproducibility and workflow efficiency. A newly introduced extraction kit addresses these needs by enabling consistent, automation-ready isolation of cfDNA from commonly used biofluids.

New England Biolabs (Ipswich, MA, USA) has launched the Monarch Mag Cell-free DNA (cfDNA) Extraction Kit for the isolation of low-abundance circulating DNA from a range of biofluids. The kit supports plasma, serum, urine and cerebrospinal fluid inputs ranging from 1 mL to 4 mL. It is positioned for workflows spanning manual processing to higher throughput with automation, and for use prior to applications including biomarker discovery and diagnostics development.

The technology employs a magnetic bead–based approach that combines specialized chemistry with silica-coated magnetic particles to efficiently recover short DNA fragments from challenging matrices, including those with high nuclease activity. Designed for automation compatibility, the streamlined workflow delivers consistent, concentrated cfDNA suitable for a broad range of downstream molecular analyses. Reported performance demonstrates recovery across the full spectrum of fragment sizes, including fragments as small as 50 base pairs.

For laboratories aiming to streamline sample‑to‑result pipelines, the kit pairs with the company’s downstream amplification and library preparation products, including the NEBNext portfolio for next generation sequencing library preparation. The format is intended to offer versatility across sample numbers, input amounts and sample types while maintaining reproducibility. Packaging updates within the Monarch portfolio reduce plastic usage in reagent bottles and packaging components compared to standard market solutions.

“Extracting cell-free DNA is uniquely challenging because it is highly fragmented and circulating at low concentrations within complex and variable biofluid matrices,” stated Anagha Kadam, Applications and Product Development Scientist II at NEB. “The kit utilizes a specialized chemistry and silica-coated magnetic beads to efficiently recover short DNA fragments from challenging samples that inherently exhibit high nuclease activity.”

“Bouncing between vendors to troubleshoot an issue is exhausting and inefficient,” said James Deng, Senior Product Marketing Manager for NEB. “With a cfDNA extraction kit that integrates seamlessly into our downstream sequencing and amplification solutions, we’re empowered to more holistically address customer challenges from sample preparation through molecular diagnostic applications.”

Related Links
New England Biolabs


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously (Photo courtesy of OptraSCAN)

New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.